Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
Data-Driven, Optimal Patient Care and Clinical Research
Expanded opportunities to advance rheumatology will be offered by ACR’s ongoing registry efforts
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
Quality Measurement Improves Rheumatology Outcomes
Innovations in health information technology can have significant impact
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
A&R Abstracts: Methotrexate
For further reading
Old Drugs Can Learn New Tricks
Methotrexate and its mechanism of action
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 125
- Next Page »